Properties (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:brand |
Ninlaro
|
| gptkbp:chemicalFormula |
C17H19N3O4S
|
| gptkbp:clinicalTrials |
combination therapy
Phase 3 monotherapy |
| gptkbp:contraindication |
severe hepatic impairment
hypersensitivity_to_ixazomib |
| gptkbp:developedBy |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:dosageForm |
capsule
|
| gptkbp:drugInterdiction |
CYP3A4 inhibitors
oral bioavailability CYP3A4 inducers |
| gptkbp:endOfLife |
9.5 hours
|
| gptkbp:firstAppearance |
2015
|
| gptkbp:hasPopulation |
adults
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ixazomib
|
| gptkbp:impact |
28 days
|
| gptkbp:is_monitored_by |
neurological symptoms
liver function tests blood cell counts |
| gptkbp:isATypeOf |
1005070-50-4
|
| gptkbp:mandates |
relapsed or refractory multiple myeloma
|
| gptkbp:marketSegment |
available
|
| gptkbp:operates_in |
L01XX32
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchAreas |
oncology
hematology |
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sells |
Ninlaro
|
| gptkbp:sideEffect |
fatigue
nausea diarrhea peripheral neuropathy thrombocytopenia |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
proteasome
|
| gptkbp:triggerType |
proteasome inhibitor
|
| gptkbp:usedFor |
multiple myeloma
|
| gptkbp:variant |
dexamethasone
lenalidomide |
| gptkbp:waterManagement |
urine
feces |
| gptkbp:weight |
357.41 g/mol
|